Article
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.
The Lancet Diabetes & Endocrinology
(2021)
Disciplines
Publication Date
April 1, 2021
DOI
10.1016/S2213-8587(21)00019-X
Citation Information
Matthias von Herrath, Stephen C Bain, Bruce Bode, Jesper Ole Clausen, et al.. "Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial." The Lancet Diabetes & Endocrinology Vol. 9 Iss. 4 (2021) p. 212 - 224 Available at: http://works.bepress.com/samer-nakhle/9/